Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Rhea-AI Summary

Market reaction after Moderna settlement payment and buyback plan: ABUS +3.95% in the Jul 16 session

+3.95%

2 alerts

+3.95% Session close to close

+2.2% Peak Tracked

-5.5% Trough Tracked

$910.65M Market Cap

0.4x Rel. Volume

In the Jul 16 session, ABUS gained 3.95%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.2% during that session. Argus tracked a trough of -5.5% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Set against a history where settlement and pipeline updates often aligned with gains of 1.28%–4.25%,...

Analysis

Set against a history where settlement and pipeline updates often aligned with gains of 1.28%–4.25%, this combination of new enforcement actions, confirmed Moderna cash receipt and an announced capital-return framework comes as short interest is moderate, keeping legal outcomes and repurchase execution as key watchpoints.

Key Figures

International lawsuits filed: 3 lawsuits Settlement payment from Moderna: approximately $178M Planned capital return: up to approximately $230M +1 more

4 metrics

International lawsuits filed 3 lawsuits Patent enforcement actions against Pfizer/BioNTech over LNP technology

Settlement payment from Moderna approximately $178M Arbutus’ share of noncontingent payment under March 2026 Settlement Agreement

Planned capital return up to approximately $230M Expected share repurchases commencing in Q3 2026, subject to board approval

Equity stake in Genevant’s parent approximately 16% Ownership of outstanding common equity tied to expected Q3 2026 dividend

Historical Context

4 past events · Latest: May 13 (Neutral)

Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
May 13	Q1 2026 earnings	Neutral	+0.0%	Quarterly results and corporate update with no material price reaction.
Apr 15	Fast Track designation	Positive	+3.0%	FDA Fast Track designation for imdusiran in chronic hepatitis B.
Mar 23	FY25 earnings update	Positive	+4.3%	Year-end results highlighting $2.25B Moderna settlement and HBV pipeline progress.
Mar 03	Moderna settlement	Positive	+1.3%	Announcement of $2.25B global patent settlement and license agreement with Moderna.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows ABUS tending to post gains following positive settlement and clinical or earnings updates.

Key Terms

lipid nanoparticle, mRNA-LNP, unified patent court, dutch auction tender offer

4 terms

lipid nanoparticle medical

"patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech"

A lipid nanoparticle is a tiny, fat‑based microscopic shell that carries and protects delicate molecules (like RNA or drugs) and helps them enter cells, similar to a microscopic delivery bubble. It matters to investors because this delivery method can make new therapies and vaccines possible or more effective, but also affects manufacturing complexity, scalability, regulatory review and cost — all of which influence a biotech company’s commercial prospects.

mRNA-LNP medical

"Pfizer/BioNTech’s mRNA-LNP COVID-19 vaccines and any other products that would infringe"

mRNA-LNP is a medical delivery technology that packages messenger RNA (mRNA) inside tiny lipid nanoparticles (LNPs) so the genetic instructions can enter cells safely and produce a protein. It matters to investors because it is the key method used in many mRNA vaccines and therapies, so advances, manufacturing capacity, regulatory outcomes, supply-chain constraints, or intellectual property around mRNA-LNPs can affect the commercial prospects and valuation of biotech companies; think of LNPs as specialized shipping containers for fragile biological cargo.

unified patent court regulatory

"Unified Patent Court (“UPC”): Case PR-UPC-CFI-0002562/2026, seeking permanent injunctions"

A unified patent court is a single legal forum that hears and decides patent disputes across multiple countries at once, acting like one central courtroom instead of many separate national courts. For investors, it matters because decisions there can affect the value and enforceability of a company’s patents across a whole region at once—similar to a single referee whose ruling changes the score for every team—impacting revenue risk, litigation costs and long-term competitive advantage.

dutch auction tender offer financial

"may come in the form of a tender offer (including a modified “Dutch Auction” tender offer)"

A Dutch auction tender offer is a method a company uses to buy back its own shares by asking shareholders to submit offers of how many shares they will sell and the minimum price they will accept. The company then chooses a single purchase price that allows it to buy the desired total number of shares, and all shareholders who bid at or below that price sell at that uniform price. For investors it matters because it determines who sells and at what price, and it can change the number of shares outstanding, market liquidity, and signals about how the company values its stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech 

Received approximately $178M from Moderna as Arbutus’ share of the noncontingent payment under the March 2026 Settlement Agreement resolving litigation over Moderna’s infringement of Arbutus’ LNP patents

Anticipates receipt of a dividend from Genevant in Q3 2026

Expects to return up to approximately $230M in capital to Arbutus shareholders

WARMINSTER, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, and its exclusive licensee, Genevant Sciences GmbH (“Genevant”) (a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV)), today announced the filing of three international lawsuits seeking to enforce patents protecting their innovative LNP technology against Pfizer Inc., BioNTech SE and certain of their affiliates (together, “Pfizer/BioNTech”). Arbutus and Genevant are seeking monetary relief, as well as injunctions against Pfizer/BioNTech’s mRNA-LNP COVID-19 vaccines and any other products that would infringe the asserted patents.

The cases are:

• Canada: Federal Court of Canada File No. T-3200-26, seeking a permanent injunction and damages or, if Arbutus and Genevant elect, an accounting of Pfizer/BioNTech’s profits, attributable to infringement of Canadian Patent No. 2,721,333
• Unified Patent Court (“UPC”): Case PR-UPC-CFI-0002562/2026, seeking permanent injunctions, as well as monetary damages, which can include recovery of Pfizer/BioNTech’s unfair profits from infringement of EP 4 241 767
• UPC: Case PR-UPC-CFI-0002566/2026, seeking permanent injunctions, as well as monetary damages, which can include recovery of Pfizer/BioNTech’s unfair profits from infringement of EP 4 495 237
  
  

The UPC actions seek relief for: Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovenia, Spain, and Sweden.

Today’s actions expand on Arbutus and Genevant’s ongoing enforcement proceeding in the U.S. District Court for the District of New Jersey, seeking fair compensation for Pfizer/BioNTech’s infringement of five U.S. patents in the manufacture and sale of Pfizer/BioNTech’s mRNA-LNP COVID-19 vaccines.

Arbutus also announced today the receipt on July 8, 2026 of approximately $178M from Moderna, Inc. (“Moderna”), representing the Company’s share of the noncontingent payment under the settlement agreement entered into with Moderna to resolve all global patent infringement litigation with Moderna related to Moderna’s COVID-19 vaccines. The payment from Moderna includes reimbursement of the Company’s litigation costs in accordance with the Company’s license agreement with Genevant. Arbutus also expects to receive a dividend from Genevant’s parent in Q3 2026, related to its ownership of approximately 16% of the outstanding common equity of Genevant’s parent.

Arbutus is also announcing that it expects to return capital to shareholders commencing in Q3 2026 through repurchases of up to approximately $230M of the Company’s common shares, which repurchases may come in the form of a tender offer (including a modified “Dutch Auction” tender offer), open market purchases, privately negotiated transactions, accelerated share repurchases or other means. The specific form(s) of any such transaction(s) remains subject to the approval of the Company’s board of directors. Any repurchase will not commence until after receipt of the expected dividend from Genevant’s parent in Q3 2026. No assurance can be given that any such repurchase activity will occur in Q3 2026, or at all.

About Arbutus  

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is currently developing imdusiran (AB-729) and an oral PD-L1 inhibitor (AB-101) for the treatment of chronic hepatitis B infection. The Company is also consulting closely with and supporting its exclusive licensee, Genevant Sciences, to protect and defend its intellectual property, which is the subject of an ongoing lawsuit against Pfizer/BioNTech for use of Arbutus’ patented lipid nanoparticle technology in their COVID-19 vaccines. For more information, visit www.arbutusbio.com.

Forward-Looking Statements and Information

This press release contains forward-looking statements and forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities laws (collectively, forward-looking statements) relating to future periods, including statements about the Company’s plans with respect to ongoing patent litigation matters; the Company’s receipt of a dividend from Genevant’s parent, and the timing thereof; and the Company’s expectation to return capital to shareholders, including the expected form and timing thereof.

The forward-looking statements contained in this press release are subject to a number of material factors that could cause actual results to differ materially, including the risk that the Company may not receive the expected dividend from Genevant’s parent on the terms or within the time expected, and that that the Company may determine not to proceed with a return of capital to shareholders for any reason. With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the timing and terms for the receipt of the expected dividend from Genevant’s parent, the Company’s financial performance, and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to uncertainties associated with litigation generally and patent litigation specifically, and significant business, economic, competitive, market and social uncertainties and contingencies. Actual results could differ materially from those currently anticipated.

A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K, Arbutus’ Quarterly Reports on Form 10-Q and Arbutus’ continuous and periodic disclosure filings, which are available at www.sedarplus.ca and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

Arbutus Biopharma Corporation / ir@arbutusbio.com